TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24393134

Group type: EXPERIMENTAL
Intervention: UMEC 125 μg QD
Number of subjects: 163

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163

Group type: COMPARATOR
Intervention: Tiotropium
Number of subjects: 163

Group type: COMPARATOR
Intervention: Other UMEC doses (15.6, 31.25, 62.5 μg)
Number of subjects: 163
Study: 21978210

Group type: EXPERIMENTAL
Intervention: Daily aphasia therapy
Number of subjects: 59

Group type: COMPARATOR
Intervention: Usual care therapy
Number of subjects: 59
Study: 19131432

Group type: EXPERIMENTAL
Intervention: NIPPV via a conventional ventilator
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: NCPAP via a variable flow device
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: NIPPV via a variable flow device
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: NCPAP via a constant flow underwater bubble system
Number of subjects: 16
Study: 17457705

Group type: EXPERIMENTAL
Intervention: Tramadol as PCA with an infusion of 0.3 mg/kg following a loading dose of 1.5 mg/kg administered 1 hour before the end of the surgery
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ondansetron 0.1 mg/kg following induction of anesthesia
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Morphine as PCA with an infusion following a loading dose of 0.15 mg/kg administered 30 minutes before the end of surgery
Number of subjects: 120
Study: 17720075

Group type: EXPERIMENTAL
Intervention: Ophthalmic review 2 hours after surgery and 2 weeks postoperatively (Group 1)
Number of subjects: 233

Group type: COMPARATOR
Intervention: No ophthalmic review before the 2-week postoperative visit (Group 2)
Number of subjects: 233
Study: 15205753

Group type: EXPERIMENTAL
Intervention: Medical registries
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized clinical trials
Number of subjects: 0
Study: 11092494

Group type: EXPERIMENTAL
Intervention: Magnevist (dimeglumine gadopentetate)
Number of subjects: 2049

Group type: COMPARATOR
Intervention: Omniscan (gadodiamide)
Number of subjects: 2049
Study: 9351750

Group type: EXPERIMENTAL
Intervention: Endocervical brush
Number of subjects: 118

Group type: COMPARATOR
Intervention: Curette (Control)
Number of subjects: 118
Study: 8212148

Group type: EXPERIMENTAL
Intervention: University of Wisconsin (UW) solution
Number of subjects: 14

Group type: COMPARATOR
Intervention: Hyperosmolar citrate (HOC)
Number of subjects: 14
Study: 3513304

Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 131
Study: 28376498

Group type: EXPERIMENTAL
Intervention: HG-sPFTC patients
Number of subjects: 22

Group type: COMPARATOR
Intervention: HG-sEOC patients
Number of subjects: 22
Study: 25922136

Group type: EXPERIMENTAL
Intervention: Maintenance check-ups (MCUs)
Number of subjects: 74

Group type: COMPARATOR
Intervention: No check-up (NCU)
Number of subjects: 74
Study: 23760999

Group type: EXPERIMENTAL
Intervention: Group led by vocational staff using the vocational manual
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Self-study using a vocational manual
Number of subjects: 111

Group type: COMPARATOR
Intervention: Basic vocational services
Number of subjects: 111
Study: 21669540

Group type: EXPERIMENTAL
Intervention: 180-minute group HIV risk-reduction counseling intervention
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Both experimental and control groups
Number of subjects: 160
Study: 19621708

Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (ADV)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 16447933

Group type: EXPERIMENTAL
Intervention: Disposable cutting head at high speed
Number of subjects: 51

Group type: COMPARATOR
Intervention: Nondisposable cutting head at low speed
Number of subjects: 51

Group type: COMPARATOR
Intervention: Disposable cutting head at low speed
Number of subjects: 51

Group type: COMPARATOR
Intervention: Nondisposable cutting head at high speed
Number of subjects: 51
Study: 15003298

Group type: EXPERIMENTAL
Intervention: Enoxaparin 20mg subcutaneous injection once daily for 3 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 11555219

Group type: EXPERIMENTAL
Intervention: Narrative virtual patient model
Number of subjects: 2

Group type: COMPARATOR
Intervention: Problem-solving virtual patient model
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group (baseline performance)
Number of subjects: 2
Study: 9543364

Group type: EXPERIMENTAL
Intervention: Methylprednisone (5 mg/kg per day in four oral doses over 7 days)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 7995913

Group type: EXPERIMENTAL
Intervention: Ultrasound attenuation measurement of calcaneum bone density
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Ultrasound attenuation measurement of lumbar vertebrae bone density
Number of subjects: 107

Group type: COMPARATOR
Intervention: Reference values from Walker Sonics machine
Number of subjects: 107

Group type: COMPARATOR
Intervention: Quantitative densitometry with computed tomography
Number of subjects: 107
Study: 3291099

Group type: EXPERIMENTAL
Intervention: Timegadine 500 mg/day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Naproxen 750 mg/day
Number of subjects: 40
Study: 31093719

Group type: EXPERIMENTAL
Intervention: IVC filters
Number of subjects: 39056
Study: 28485008

Group type: EXPERIMENTAL
Intervention: L-carnosine as adjuvant to fluvoxamine
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo as adjuvant to fluvoxamine
Number of subjects: 44
Study: 25212871

Group type: EXPERIMENTAL
Intervention: Clopidogrel (300 mg for the first day, 75 mg/day thereafter) plus aspirin (100 mg/day)
Number of subjects: 690

Group type: COMPARATOR
Intervention: Aspirin alone (300 mg/day)
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin
Number of subjects: 690

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 690
Study: 24377217

Group type: EXPERIMENTAL
Intervention: Jin's three-needle therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Rehabilitation therapy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combined therapy (acupuncture and rehabilitation)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: All groups (Jin's three-needle, rehabilitation, combined therapy)
Number of subjects: 100
Study: 21953629

Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 19501656

Group type: EXPERIMENTAL
Intervention: Verum acupuncture with high expectancy
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Verum acupuncture with low expectancy
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: All four groups (including verum and control)
Number of subjects: 48
Study: 16995460

Group type: EXPERIMENTAL
Intervention: Prophylactic band ligation and propranolol
Number of subjects: 72

Group type: COMPARATOR
Intervention: Propranolol alone
Number of subjects: 72
Study: 14988282

Group type: EXPERIMENTAL
Intervention: Self-reported energy intake (EI)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Energy underreporters
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: EI-to-TEE ratio
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Demographic variables, BMI, and following a diet for diabetes
Number of subjects: 200
Study: 11246353

Group type: EXPERIMENTAL
Intervention: 2 L of PEG‐ELS with 20 mg bisacodyl
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 2 L of PEG‐ELS preceded by 296 mL of magnesium citrate
Number of subjects: 68

Group type: COMPARATOR
Intervention: 4 L of PEG‐ELS
Number of subjects: 68
Study: 9141518

Group type: EXPERIMENTAL
Intervention: MK-386 0.1 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: MK-386 0.5 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: MK-386 5 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: MK-386 20 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: MK-386 50 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg
Number of subjects: 100
Study: 8153915

Group type: EXPERIMENTAL
Intervention: Aminophylline (administered continuously for 48 hours after surgery)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Aminophylline (administered for 24 hours after cholecystectomy)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo (control group, administered for 24 hours after cholecystectomy)
Number of subjects: 37
Study: 3528979

Group type: EXPERIMENTAL
Intervention: Oral dexamethasone
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 31479537

Group type: EXPERIMENTAL
Intervention: Multicomponent quality improvement intervention including non‐physician care coordinators and clinical decision‐support software
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multicomponent quality improvement intervention
Number of subjects: 0
Study: 30346655

Group type: EXPERIMENTAL
Intervention: Milk powder co-supplemented with inulin and resistant dextrin (MPCIR)
Number of subjects: 0
Study: 26432031

Group type: EXPERIMENTAL
Intervention: Interpersonal Counselling (IPC), 7 sessions
Number of subjects: 40

Group type: COMPARATOR
Intervention: Interpersonal Psychotherapy (IPT), 16 sessions
Number of subjects: 40
Study: 25614600

Group type: EXPERIMENTAL
Intervention: Dopamine infusion (2 μg·min(‐1)·kg(‐1)) at rest
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Hyperoxia (100% oxygen) at rest
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Dopamine infusion during handgrip (HG) exercise
Number of subjects: 21

Group type: COMPARATOR
Intervention: Handgrip (HG) exercise
Number of subjects: 21
Study: 23940227

Group type: EXPERIMENTAL
Intervention: DA (daunorubicin and cytarabine)
Number of subjects: 1983

Group type: COMPARATOR
Intervention: ADE (daunorubicin, cytarabine, etoposide)
Number of subjects: 1983

Group type: COMPARATOR
Intervention: FLAG-Ida (fludarabine, cytarabine, G-CSF, idarubicin)
Number of subjects: 1983

Group type: EXPERIMENTAL
Intervention: MACE-MidAC (amsacrine, cytarabine, etoposide, mitoxantrone/cytarabine)
Number of subjects: 1983

Group type: COMPARATOR
Intervention: High-dose cytarabine (1.5 g/m2 or 3 g/m2)
Number of subjects: 1983

Group type: EXPERIMENTAL
Intervention: Cytarabine (1.5 g/m2)
Number of subjects: 1983

Group type: EXPERIMENTAL
Intervention: Fifth course (cytarabine)
Number of subjects: 1983

Group type: EXPERIMENTAL
Intervention: FLAG-Ida (two courses) and cytarabine (two courses)
Number of subjects: 1983
Study: 22314671

Group type: EXPERIMENTAL
Intervention: Acu-TENS
Number of subjects: 44
Study: 18340256

Group type: EXPERIMENTAL
Intervention: Intensive short-term dynamic psychotherapy (ISTDP)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Minimal-contact, delayed-treatment control condition
Number of subjects: 27
Study: 17154774

Group type: EXPERIMENTAL
Intervention: Tone discrimination task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reading aloud task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Orthographic neighborhood density
Number of subjects: 0
Study: 12665158

Group type: EXPERIMENTAL
Intervention: Dihydrocodeine (60 mg single dose)
Number of subjects: 9
Study: 11194454

Group type: EXPERIMENTAL
Intervention: Polyadenylic-polyuridylic acid plus locoregional radiotherapy
Number of subjects: 517

Group type: COMPARATOR
Intervention: CMF (Control)
Number of subjects: 517
Study: 9151543

Group type: EXPERIMENTAL
Intervention: Various concurrent recruitment methods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regular monitoring of recruitment efficiency
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Careful planning and attention to product design and staff training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complex trial designs (e.g., pre-randomization placebo run-in, split-mouth designs)
Number of subjects: 0
Study: 8400972

Group type: EXPERIMENTAL
Intervention: 200 mg mifepristone + 1 mg gemeprost
Number of subjects: 1182

Group type: EXPERIMENTAL
Intervention: 400 mg mifepristone + 1 mg gemeprost
Number of subjects: 1182

Group type: EXPERIMENTAL
Intervention: 600 mg mifepristone + 1 mg gemeprost
Number of subjects: 1182
Study: 2448908

Group type: EXPERIMENTAL
Intervention: Disposable drainage system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glass drainage system
Number of subjects: 0
Study: 31654548

Group type: EXPERIMENTAL
Intervention: Human fibrinogen concentrate (HFC; 4 g)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Cryoprecipitate (two pools of 5 units, approximately 4.0-4.6 g fibrinogen)
Number of subjects: 43
Study: 28222627

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg once daily
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg three times daily
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 388

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 388
Study: 26354542

Group type: EXPERIMENTAL
Intervention: Improving dietary quality (increased fruit by +1 serving; 150 g/d, vegetables by +2 servings; 150 g/d, and dairy by +1 serving; 200-250 g/d)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Improving dietary quality (increased fruit and vegetable intake)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Improving dietary quality (yogurt intake)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group (usual diet)
Number of subjects: 118
Study: 23026870

Group type: EXPERIMENTAL
Intervention: Real acupuncture treatment
Number of subjects: 130

Group type: COMPARATOR
Intervention: Sham acupuncture treatment
Number of subjects: 130
Study: 20354496

Group type: EXPERIMENTAL
Intervention: Low-volume zero-balanced ultrafiltration (35 mL/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 18207289

Group type: EXPERIMENTAL
Intervention: LGT/DEN4 vaccine (10^3 PFU)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 16607233

Group type: EXPERIMENTAL
Intervention: Epoetin alfa, 40,000 IU, administered subcutaneously once weekly (n=48)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo (n=25)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 14603056

Group type: EXPERIMENTAL
Intervention: Lateral pharyngoplasty
Number of subjects: 10
Study: 12869080

Group type: EXPERIMENTAL
Intervention: 40 mg of oral baclofen
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 11798621

Group type: EXPERIMENTAL
Intervention: Sparfloxacin
Number of subjects: 212

Group type: COMPARATOR
Intervention: Ofloxacin
Number of subjects: 212
Study: 8605131

Group type: EXPERIMENTAL
Intervention: Goserelin acetate (3.6 mg subcutaneously)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Goserelin acetate (3.6 mg subcutaneously) for 8 weeks
Number of subjects: 160

Group type: COMPARATOR
Intervention: Both treatment regimens (Goserelin and Danazol)
Number of subjects: 160
Study: 1857247

Group type: EXPERIMENTAL
Intervention: Check-box format
Number of subjects: 547

Group type: COMPARATOR
Intervention: Open-ended questions
Number of subjects: 547
Study: 6355421

Group type: EXPERIMENTAL
Intervention: Captopril (0.5, 1.0, and 2.0 mg/kg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Captopril (after 1 week of treatment)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Captopril combined with hydrochlorothiazide
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Captopril clearance
Number of subjects: 10
Study: 3987782

Group type: EXPERIMENTAL
Intervention: Prazosin once daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Prazosin twice daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 20
Study: 30081390

Group type: EXPERIMENTAL
Intervention: TAU plus twice-weekly medication reminders by SMS (n=62)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Treatment as usual (TAU; n=70)
Number of subjects: 132

Group type: COMPARATOR
Intervention: TAU (n=70)
Number of subjects: 132
Study: 26565928

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT) program, 7-week duration
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 52
Study: 26401779

Group type: EXPERIMENTAL
Intervention: Soy isoflavones (100 mg/day)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 23818206

Group type: EXPERIMENTAL
Intervention: Chinese medicine (CM)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Montelukast tablets and theophylline
Number of subjects: 94
Study: 21426747

Group type: EXPERIMENTAL
Intervention: Surgery (uvulopalatopharyngoplasty)
Number of subjects: 382
Study: 18679092

Group type: EXPERIMENTAL
Intervention: Bryan cervical disc prosthesis (n=242)
Number of subjects: 463

Group type: COMPARATOR
Intervention: Anterior cervical discectomy and fusion with an anterior cervical plate (n=221)
Number of subjects: 463
Study: 17132970

Group type: EXPERIMENTAL
Intervention: Memantine (20 mg per day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 0
Study: 12828502

Group type: EXPERIMENTAL
Intervention: SLI‐381 10, 20 or 30mg once daily
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: SLI‐381
Number of subjects: 563

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 563
Study: 10866908

Group type: EXPERIMENTAL
Intervention: Continuous infusion at 10 mL/h (Group 1)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Continuous infusion at 5 mL/h plus PCA boluses (2.5 mL/30 min) (Group 2)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: PCA boluses only (10 mL/60 min) (Group 3)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 45
Study: 9103270

Group type: EXPERIMENTAL
Intervention: Brussels sprouts (300 g per day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Glucosinolate-free vegetables (300 g per day)
Number of subjects: 10
Study: 8403942

Group type: EXPERIMENTAL
Intervention: Indobufen
Number of subjects: 52

Group type: COMPARATOR
Intervention: ASA plus dipyridamole
Number of subjects: 52
Study: 3095082

Group type: EXPERIMENTAL
Intervention: Ritanserin 10 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ritanserin 20 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ritanserin (10 mg and 20 mg)
Number of subjects: 12
Study: 31515632

Group type: EXPERIMENTAL
Intervention: NZBC extract (600 mg day-1 CurraNZ™ containing 210 mg anthocyanins)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: NZBC extract
Number of subjects: 18

Group type: COMPARATOR
Intervention: Both NZBC extract and PL
Number of subjects: 18
Study: 29772028

Group type: EXPERIMENTAL
Intervention: CPHPC (miridesap) for SAP depletion prior to DNA vaccination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no SAP depletion)
Number of subjects: 0
Study: 26831857

Group type: EXPERIMENTAL
Intervention: Navigation-assisted TKA
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional TKA
Number of subjects: 80
Study: 25030803

Group type: EXPERIMENTAL
Intervention: Pregnenolone
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 22851599

Group type: EXPERIMENTAL
Intervention: Telephonic intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active control (print intervention)
Number of subjects: 0
Study: 20800270

Group type: EXPERIMENTAL
Intervention: Thermo-mechanical loading (TML; 100,000×50N; 2500×+5/+55°C)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Water storage (WS)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Water storage plus thermo-mechanical loading (WS+TML)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Direct resin composite restorations (in vivo)
Number of subjects: 30
Study: 18583016

Group type: EXPERIMENTAL
Intervention: Interactive voice and video instruction (video group)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Voice instruction alone (voice group)
Number of subjects: 96
Study: 16647134

Group type: EXPERIMENTAL
Intervention: Pegaptanib sodium (0.3 mg)
Number of subjects: 1190

Group type: EXPERIMENTAL
Intervention: Pegaptanib sodium (1 mg)
Number of subjects: 1190

Group type: EXPERIMENTAL
Intervention: Pegaptanib sodium (3 mg)
Number of subjects: 1190

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 1190
Study: 12960445

Group type: EXPERIMENTAL
Intervention: 500 mg hydroxy‐progesterone caproate and 10 mg oestradiol valerate on days 2, 6, 10 and 14 after embryo transfer (group 2, n = 411)
Number of subjects: 603

Group type: COMPARATOR
Intervention: 5000 iu human chorionic gonadotrophin (hCG) 4 and 8 days after embryo transfer (group 1, n = 534)
Number of subjects: 603
Study: 10731545

Group type: EXPERIMENTAL
Intervention: Stroop Color Word test and blood sampling in patients with FHSA
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Stroop Color Word test and blood sampling in patients with PCOS
Number of subjects: 90

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Patients with PCOS
Number of subjects: 90
Study: 9491671

Group type: EXPERIMENTAL
Intervention: Late progesterone phase
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Regular menstrual cycles
Number of subjects: 53
Study: 1550514

Group type: EXPERIMENTAL
Intervention: Isotope renography
Number of subjects: 63

Group type: COMPARATOR
Intervention: Arteriography
Number of subjects: 63
Study: 2866057

Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31191092

Group type: EXPERIMENTAL
Intervention: Foam Rolling (FOAM, n = 14)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Core Stabilization (CORE, n = 12)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control Group (CG, n = 12)
Number of subjects: 40
Study: 28813214

Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 1204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1204